SEPTEMBER 07, 2022
Biophytis released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure
JULY 4, 2022
Biophytis to update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Phase 2-3 COVA study results expected in Q3 2022 Biophytis announces its CEO, Stanislas Veillet, PhD, has been hosting a presentation at the 4th Annual Longevity Therapeutics Summit in San Francisco. The Biophytis presentation entitled “Discussing the…
JUNE 30, 2022
Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million Biophytis announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based…
JUNE 27, 2022
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress Biophytis announced that it is giving an oral presentation on the development of Sarconeos (BIO101) for the treatment of sarcopenia at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders). This…
JUNE 22, 2022
Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the…
JUNE 16, 2022
Biophytis announced that it is presenting new preclinical efficacy data for its product Sarconeos (BIO101) in SMA (Spinal Muscular Atrophy) at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022. This oral presentation given by Dr. Cynthia Bézier and entitled: “COMBINATION OF BIO101 WITH ANTISENSE OLIGONUCLEOTIDE THERAPY DEMONSTRATES SYNERGISTIC BENEFICIAL EFFECTS…
JUNE 3, 2022
Convening of Another Combined General Meeting at a Later Date Biophytis informs its shareholders that the combined Annual General Meeting (AGM) held on June 3, 2022 was unable to deliberate, as the required quorum was not reached. The shareholders taking part in the vote owned collectively 23 514 980 shares, or 15.45% of the share…
MAY 12, 2022
Biophytis announces its participation at the BIO International Convention in San Diego from the 13th to the 16th of June Biophytis announces it will participate, represented by its CEO Stanislas Veillet and its Business Development Director Benoit Canolle, at the Biotechnology Innovation Organization (BIO) International Convention to be held in San Diego from the 13th…
APRIL 19, 2022
Biophytis presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022 Biophytis announces it will present and discuss the results of Sarconeos (BIO101) development program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) to be…
APRIL 07, 2022
Biophytis announces its audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022 Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid…